Researchers conducted a retrospective study using data from 182 subjects with high-risk recurrent prostate cancers.

Radical prostatectomy is a standard treatment for prostate cancer, yet about 30% of patients experience rising biochemical markers within a decade post-surgery. Pelvic lymph node sampling during ...

Cemiplimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Penile Cancer.

Long before mRNA vaccines captured global attention during the COVID-19 pandemic, researchers were already exploring their ...